glucosidase from human placenta (I1* 26) and spleen (I5). This sitivity of the enzyme assay for ~~~~h~~'~ disease can be enhanced clearly demonstrated the variable tissue specificity of P-glucosiby determining ~-~l~~~~i d~~~ activity in both the absence and dase; i.e., enzyme from different sources reacted differently with presence of purified sodium taurocholate, particularly when variant sodium taurocholate. Therefore, it seemed important to study the cases with relatively high residual enzyme activity are encountered. effects taurochO1ate On P-glucosidase In contrast to the enzyme from fibroblasts and spleens, P-glucos-human skin a source enzyme for the idase activity from human placenta was activated ( , diagnosis of Gaucher's disease as well as for biochemical studies 300%) by the presence of 0.08% (1.49 m~) purified sodium tau-in man. In addition, the recent report of an electrophoretic techrwholate or 0.1 ,,,M phosphatidyl serine, suggesting the presence nique for the detection of ,@-glucosidase isozymes in human tissues of a predominate form of ~-~l~~~~i d~~~, g~ucocerebroside had revealed concomitantly that P-glucosidase is a highly tissue-8-glucosidase, which is activated by the detergent. The apparent Specific enzyme (10) . In this report are the results of studies of the ~i~h~~l i~ constant ( K~) for both the soluble and membraneeffect of sodium taurocholate on P-glucosidase activity from culbound enzyme from fibroblasts was 1.6 0.1 K~~ tured skin fibroblasts as compared to that from the placenta and from a patient with severe juvenile Caucher's disease and two with data that provide further for the other patients with milder manifestations were 0.8 f 0.2 and 3.3 a enzyme in Gaucher's disease. f 0.3 mM, respectively.
These studies also provide useful information for the establishment of a more sensitive and reproducible assay method in the Speculation presence of this detergent for the diagnosis of Gaucher's disease, particularly when variant cases are encountered. The observation that 8-glucosidase activity from tissues of patients with juvenile onset forms of Gaucher's disease is prefer-MATERIALS AND METHODS entially inhibited by the detergent, sodium taurocholate, suggests that a structurally altered-P-glucosidase, which is more susceptible Sodium taurocholate (grade A) was the product of Calbiochemto inhibition by sodium taurwholate, is synthesized in patients icals, La Jolla, California. Crude sodium taurocholate, chemically with the disease. The severity of the disease could depend on the synthesized (98% pure) sodium taurocholate, and phosphatidyl particular amino acid aff'ected in the primary structure of the serine were the products of Sigma Chemical Co., St. Louis, enzyme. An alternate explanation is the presence of at least two Missouri. 4-Methylumbelliferone (4 MU) and 4 MUGP were enzymes, which may or may not be isozymes, each capable of obtained from Koch Light Labs Ltd., Coinbrook, Bucks, England. releasing glucose from the artificial fluorogenic substrate, but only All patients. except one, were of non-Jewish ancestry as far as one, which is deficient in Gaucher's disease, can hydrolyse the is known. Patient I (Table 1) is half Jewish: his father is ar natural substrate and is unaffected by the presence of sodium Ashkenazi Jew; his mother, a non-Jewish Swede. ~l t h o u~h the taurocholate.
clinical manifestations were highly variable, none showed any sign of neurologic deterioration and all would, therefore, be classified as type I. Glucocerebrosidase (glucosylceramidase, EC 3.2.1.45) is a lySkin fibroblasts were obtained from punch biopsies, culturec sosomal enzyme that cleaves the P-glucosidic bond of the glyw-and harvested as previously described (10) . Fibroblast homoge-nates were prepared by multiple freeze-thawing of the cell suspension in an ethylene glycol dry-ice bath consecutively for five times. Placentas were obtained after normal deliveries in the local obstetrical unit. Spleen and liver specimens were obtained at autopsy or biopsy. All tissues were stored at -70°C until used. Homogenates and tissue extracts from these organs were prepared as previously described (10) . Leukocytes were isolated from fresh human venous blood by a dextran gradient (1) and extracts were prepared in the same manner as for fibroblasts (10) . P-glucosidase was assayed at 37°C by adding 10 p1 of enzyme preparation, which contained 10-40 pg protein, to a reaction mixture comprised of 70 pl of 3.0 mM 4 MUGP, 15pl of 0.2 M citrate buffer, pH 4.5 or at other pH, and 5 p1 of water or sodium taurocholate at various concentrations. Each assay tube contained the same amount of protein as enzyme source unless otherwise stated. The reaction mixture was incubated for 30-60 min, and the reaction was stopped by the addition of 1.5 m10.2 M glycine buffer, pH 10.5. 4 MU P-glucosidase activity was determined by the intensity of fluorescence emitted, as previously described (10) .
For kinetic studies, varied amounts of 4 MUGP were included in the reaction mixture and the reaction was stopped after 30 min of incubation at 37°C.
The effect of phospholipids on P-glucosidase activity was studied according to the method of Dale et al. (12) . Protein was measured by the method of Lowry et al. (20) .
I RESULTS P-glucosidase activity from cultured skin fibroblasts of three atients with juvenile onset Gaucher's disease and three normal is shown in Table I . Results of the P-glucosidase activity observed to be consistent and reproducible from cells uring their 4th-19th passages. The inhibitory effects of crude and A) sodium taurocholate on P-glucosidase from juvenile onset Gaucher fibroblast homogenates Figure 1 . In Gaucher fibroblasts, inhibition of Pglucosidase activity by sodium taurocholate was observed at concentrations as low as 0.025% (0.46 mM). This decrease in activity was proportional to the amount of sodium taurocholate in the reaction assay mixture. P-glucosidase activity in normal fibroblasts was not affected by the presence of sodium taurocholate at low concentrations. When purified sodium taurocholate was used ( Fig.  la) , there was a gradual decrease in enzyme activity at concentrations higher than 0.1% (1.86 mM). Similar observations were noted when chemically synthesized sodium taurocholate was used. In addition, the crude sodium taurocholate was more potent in inhibiting P-glucosidase activity in both normal and Gaucher fibroblasts (Fig. 1 b) .
When the amounts of Gaucher fibroblast homogenates added to the enzyme assay mixture were increased so that P-glucosidase activity was equivalent to that of normal controls, similar preferential inhibition of /?-glucosidase activity was observed.
Very high background fluorescence was noted in the crude bile salt. Thus, in calculating P-glucosidase activity in the presence of crude sodium taurocholate, care must be taken to subtract this background fluorescence. Otherwise, artificially high readings will result which appear to indicate enhancement of P-glucosidase activity. In addition, batches of crude taurocholate from different manufacturers gave results which were not comparable.
Because sodium taurocholate is the salt of a weak acid and strong base (taurocholic acid and sodium hydroxide), the pH of a 0.5% solution is 8.5. In order to be certain that the decrease in Pglucosidase activity at higher concentrations of sodium taurocholate is not due to an elevation in the pH of the enzyme assay system above its optimum, the pH of the final substrate buffer reaction mixture was measured. There was no appreciable change in pH within the range of sodium taurocholate concentrations employed. The pH was 4.55 at 0.5% as compared to 4.50 at 0%.
The effects of sodium taurocholate on /I-glucosidase activity in normal and Gaucher spleens are shown in Table 2 . As observed in the cultured fibroblasts, P-glucosidase from Gaucher spleens was preferentially inhibited by 0.5%(9.3 mM) sodium taurocholate. This phenomenon was observed in the crude tissue homogenates, in the supernatant after centrifugation at 40,000 x g for 1 hr, and in the residual pellet. In the residual pellet, P-glucosidase was slightly enhanced in the controls but markedly inhibited in the patients.
In contrast to the enzyme of fibroblasts and spleen, P-glucosidase activity from placental extracts was greatly activated by the presence of purified sodium taurocholate (Fig. 2) . A 300% enhancement in activity was observed in the presence of 0.08% (0.46 mM) sodium taurocholate. In marked contrast, crude sodium taurocholate inhibited P-glucosidase activity. There was a gradual decrease in enzyme activity as the amount of crude sodium taurocholate in the assay mixture was increased (Fig. 2) . P-glucosidase from human placenta had been reported to be activated in the presence of various acidic phospholipids (12) . Because /3-gluwsidase from the placenta was the only enzyme in Fig. 1 . a, The effect of purified sodium taurocholate on P-gluwsidase activity from normal and Gaucher fibroblast homogenates. Cultured sk fibroblasts from patient 3 were used. Similar results were also observed from cultured skin fibroblasts of patients I and 2. b, The effect of crude sodi~ taurocholate on P-glucosidase activity from normal and Gaucher fibroblast homogenates. The effect of sodium taurocholate on P-gluwsidase activity from placental extracts. these studies to be activated significantly by purified sodium taurocholate, the authors studied the.effect of phosphatidyl serine, an acidic phospholipid, on P-glucosidase activity from various human tissues. As shown in Figure 3 , when assayed in the presence of 0.1 mM phosphatidyl serine, activities were severely diminished in crude liver extracts, in a 40-fold partially purified liver preparation and in crude spleen extracts. Enzyme activity was moderately diminished in leukocyte extracts, but in the placenta Pglucosidase activity was dramatically increased (36Wo) when assayed in the presence of this phospholipid.
Previous data suggested that synthesis of a structurally altered enzyme is the basic defect in Gaucher's disease (10) . If this hypothesis is correct, P-glucosidase in patients with Gaucher's disease should possess different kinetic properties from the normal enzyme. In order to avoid the complication of mixed kinetics (13) I I when isozymes of P-glucosidase may be present in the assay system (17), fibroblast homogenates (freeze-thawed x 10) were centrifuged at 48,000 x g for 1 hr at 3OC to separate the membranebound form of the enzyme from the soluble enzyme in the supernatant. The pellet after centrifugation was resuspended and mixed thoroughly in 3 volumes of ice-chilled isotonic saline, centrifuged, and resuspended in saline. This procedure was repeated until no further soluble p-glucosidase could be detected in the 48,000 x g supernatant. Kinetic properties of p-glucosidase in the supernatant (soluble enzyme) and pellet (membrane-bound enzyme) were then determined and the results are shown in Figure  4 . The apparent Michaelis constant for both the soluble and membrane-bound enzyme was 1.6 1 0 . 1 mM. Additionally, when 3.12% crude sodium taurocholate was included in the assay system for membrane-bound P-glucosidase, a noncompetitive type of inhibition was observed. Very different kinetics were observed with the membrane5ound /?-glucosidase from the fibroblasts of three patients with uvenile Gaucher's disease (Fig. 5) . As well as having much lower Vmax values, the apparent Michaelis constants were very different 'rom each other and from the normal controls. The Km of nembrane-bound /I-glucosidase from three normal controls was 1.6 + 0.1 mM. Kms from a patient with severe juvenile Gaucher's disease and two other patients with milder manifestations were 1.8 -+ 0.2 mM and 3.3 & 0.3 mM, respectively.
During the course of these studies, a 4-yr-old boy with splenonegaly and mild hypersplenism was seen. The possibility of Saucher's disease was raised. p-glucosidase activity assayed from iis leukocytes was 25% of normal, but enzyme activity from his :ultured fibroblasts assayed in the absence of sodium taurocholate was within the lower limit of normal range (Fig. 6) . However, when sodium taurocholate was added to the assay system, ,8-;lucosidase activity was dramatically decreased. The diagnosis of Saucher's disease was further confirmed by the abnormal electro3horetic pattern of /3-glucosidase from his leukocyte extracts (10). 
8 CHOY AND DISCUSSION
Sodium taurocholate had been shown to stimulate and stabilize P-glucocerebrosidase activity from the spleen (15) and the placenta (I I, 12, 26) , and has become a standard component of the assay system. However, the effect of the purified bile salt on P-glucosidase activity from cultured skin fibroblasts and peripheral blood leukocytes when the fluorogenic substrate, 4 MUGP, is used for the diagnosis of Gaucher's disease (2, 3, 17, 19, 28) has not been described. Sodium taurocholate from different commercially available sources may also result in very different findings depending on the purity of the product. In this paper, the authors have studied the effect of sodium taurocholate from various sources on P-glucosidase activities in different human tissues and established a sensitive assay procedure for the diagnosis of Gaucher's disease using the fluorogenic substrate, 4 MUGP. The finding that P-glucosidase from Gaucher fibroblasts is more susceptible to inhibition by crude or purified taurocholate than the normal enzyme can be applied to enhance the sensitivity of the assay system, especially when variant cases are encountered (Fig.  6) . Because of the heterogeneity and complexity of this metabolic disorder, wherein tissues from patients with Gaucher's disease may have P-glucosidase deficiency (8, 18, 22) , multiple glycosidase deficiencies (9), or normal levels of enzyme activity (7, 16, 23) towards artificial P-glucoside substrates, enzyme assay for the diagnosis of Gaucher's disease using the fluorogenic substrate 4 MUGP should be performed in both the absence and presence of purified sodium ta-urocholate.
If the basic enzymatic defect in Gaucher fibroblasts were a deficient amount of structurally normal P-glucosidase, then the amount of enzyme added to the reaction mixture would be less than that in the normal controls. In that case, the apparent preferential inhibition of P-glucosidase activity from Gaucher fibroblasts by excess sodium taurocholate would simply be an artefact resulting from that excess. In order to eliminate that possibility, the amount of fibroblast homogenate from patient 3 (whose B-glucosidase activity level is approximately one-third of normal, as shown in Table I ) was tripled in the enzyme assay. The preferential inhibition of P-glucosidase activity by the detergent remained. This same phenomenon was also observed in fibroblasts of two other patients with juvenile Gaucher's disease (Table 1 , patients 1 and 2).
Similar effects of sodium taurocholate on P-glucosidase activity were observed in the homogenates, supernatant and residual fractions of the two control and five Gaucher spleens in that 8-glucosidase from the Gaucher spleens appeared to be more susceptible to inhibition by this bile salt. This observation was in accordance with findings of Peters et al. (27) who reported an 80% inhibition of P-glucosidase in Gaucher splenic homogenates in the presence of 0.6% sodium taurocholate. Based on this and other studies of the human liver, they concluded that human tissue contains at least two enzymes capable of releasing glucose from 4 MUGP, but only one of these enzymes can hydrolyse gluwcerebroside; the latter is deficient in individuals with Gaucher's disease. This may partially explain the preferential inhibitory effect of sodium taurocholate on ,i?-gluwsidase in Gaucher tissues. The nonspecific P-glucosidase present in patients with Gaucher's disease is selectively inhibited, whereas the gluwcerebrosidase deficient in Gaucher's disease is stimulated in normal tissues. The distribution of these two P-glucosidases varies in different tissues. In the placenta, glucocerebrosidase is presumably the predominant form, as more than a 3000/0 increase in P-gluwsidase activity was observed in the presence of purified sodium taurocholate (Fig. 2) . Similarly, phosphatidyl serine may play the same role by inhibiting the nonspecific P-glucosidase activity and stimulating glucocerebrosidase activity (Fig. 3) .
The fmdings that purified sodium taurocholate should be used exclusively in the diagnosis of Gaucher's disease using the fluorogenic substrate is in accordance with a recent report by Wenger et al. (32) . Crude sodium taurocholate was observed to interfere with the assay of P-glucosidase activity from leukocytes and to DAVIDSON create high background fluorescence (32) . Purified sodium taur cholate from Calbiochemicals, as employed in these experiment note is the observation that the apparent Michaelis constants (Km) of P-glucosidase from different Gaucher fibroblasts are different from each other in addition to being different substantially from may be the result of a mut specifying the structure of /3-gl disease could depend on the mutation in the primary structure o f t especially if it involves the catalytic affect the specificity and affinity of the substrat as well as the enzyme catalytic ability to con into its products.
disease is a mutation of glucocerebrosidase which results in sodium taurocholate-treated fibroblast homogenates or ex from normal individuals and patients with juvenile and onset Gaucher's disease, residual P-glucosidase activities i lipidotic cells were found to have increased not be distinguished from that in normal c exclusion properties (21), Michaelis cons from the different e methods. In our kinetic studies, both the membrane-bound glucosidase preparation and the assay system did detergent, whereas Triton X-100 and sodium taurocholate we normal cells (30) , which is the result of a genetic mutation at thc structural gene locus (31) . This may explain why the mutatec enzyme in Gaucher fibroblasts is more susceptible to heat inacti vation (21, 3 1) and to inhibition by sodium taurocholate. 
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